Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit

NCT ID: NCT02226809

Last Updated: 2014-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

763 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Residual neuromuscular block (RNMB) is frequent in the immediate postoperative period and is a source of complications, mainly respiratory. The incidence is variable due to multiple factors. In Spain the incidence is unknown.

The investigators hypothesize that a number of patients in the postanesthesia care unit (PACU) present with RNMB after general anesthesia using intermediate action neuromuscular block agents (NMBA).

The main objective is to know the incidence of RNMB in Spanish hospitals. Secondary objectives are to observe the possible relationship with other pre- and intraoperative factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Residual neuromuscular block (RNMB) is frequent in the immediate postoperative period and is a source of complications, mainly respiratory. This includes recovery delay or hospital discharge delays, respiratory insufficiency or infections, unforeseen ICU admissions, and prolonged ICU stays.

The incidence is variable due to multiple factors. Age, gender, surgery, NMBA type and doses, temperature, medications, etc.

In several studies it has been found and incidence between 6-80%. Few studies have been focused in evaluating the incidence in the whole country, as representing a global anesthesia practice. In Spain the incidence is unknown.

The investigators hypothesize that a number of patients in the postanesthesia care unit (PACU) present with RNMB after general anesthesia using intermediate action NMBA.

The main objective is to know the incidence of RNMB in Spanish hospitals, by means of an observational cross-sectional multicenter study .

Secondary objectives are to observe the possible relationship with other pre- and intraoperative factors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incomplete Reversal of Neuromuscular Block Postoperative Respiratory Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

General anesthesia

Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose

Accelerometry

Intervention Type DEVICE

Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Accelerometry

Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TOF-Watch

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients \>18 years-old
* General anesthesia with non-depolarizing NMBA
* Transferred extubated on spontaneous ventilation to the PACU

Exclusion Criteria

* American Society of Anesthesiologists physical status IV-V
* emergency and cardiac surgery
* patients unable to respond adequately at the moment of pre- or postoperative evaluation (psychiatric diseases, excessive somnolence, agitation, etc.)
* noncompensated diabetes mellitus or diabetic neuropathy
* symptomatic severe hypothyroidism (or untreated), or scheduled for total thyroidectomy
* chronic or acute renal insufficiency
* severe hepatopathy (Child-Pugh B, C)
* intraoperative blood transfusion \>3 blood units
* intraoperative maintained arterial hypotension
* arrival to the PACU intubated or with instrumented airway (including surgical)
* pre- or perioperative drugs intake affecting the neuromuscular transmission
* neuromuscular diseases affecting the physiology of the neuromuscular system
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

General University Hospital of Valencia

OTHER

Sponsor Role collaborator

Hospital General Universitario Gregorio Marañon

OTHER

Sponsor Role collaborator

University of Valencia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carlos Luis Errando

MD, PhD, staff anesthesiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carlos L Errando, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Servicio de Anestesiologia. Consorcio Hospital General Universitario de Valencia

Ignacio Garutti, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Servicio de Anestesiologia. Hospital Universitario Gregorio Marañon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital General de Elda

Elda, Alicante, Spain

Site Status

Hospital de Bellvitge

Badalona, Barcelona, Spain

Site Status

Hospital Universitario Germans Trias i Pujol

Badalona, Barcelona, Spain

Site Status

Hospital Clinic Universitari

Barcelona, Barcelona, Spain

Site Status

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Site Status

Hospital General de Castellón

Castellon, Castellón, Spain

Site Status

Complejo Hospitalario Universitario

A Coruña, Coruña, Spain

Site Status

Hospital Universitario Reina Sofía

Córdoba, Córdoba, Spain

Site Status

Hospital Universitario Virgen de las Nieves

Granada, Granada, Spain

Site Status

Hospital San Pedro

Logroño, La Rioja, Spain

Site Status

Hospital Universitario Lucus Augusti

Lugo, Lugo, Spain

Site Status

Hospital Severo Ochoa

Leganés, Madrid, Spain

Site Status

Hospital Universitario de la Princesa

Madrid, Madrid, Spain

Site Status

Hospital General Universitario Gregorio Marañón

Madrid, Madrid, Spain

Site Status

Hospital Ramón y Cajal

Madrid, Madrid, Spain

Site Status

Hospital Fundación Jiménez Díaz

Madrid, Madrid, Spain

Site Status

Hospital de Manacor

Manacor, Palma de Mallorca, Spain

Site Status

Hospital Universitario Son Espases

Palma de Mallorca, Palma de Mallorca, Spain

Site Status

Hospital Xeral de Vigo

Vigo, Pontevedra, Spain

Site Status

Hospital Clinico Universitario de Valencia

Valencia, Valencia, Spain

Site Status

Hospital Arnau de Vilanova

Valencia, Valencia, Spain

Site Status

Hospital Universitario Dr Peset

Valencia, Valencia, Spain

Site Status

Hospital Universitario Politécnico La Fe

Valencia, Valencia, Spain

Site Status

Hospital Universitario Basurto

Basurto, Vizcaya, Spain

Site Status

Hospital Miguel Servet

Zaragoza, Zaragoza, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CEO-BNM-2014-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.